C5 and paroxysmal nocturnal hemoglobinuria: Eculizumab and ravulizumab prevent intravascular hemolysis and thrombosis among PNH patients however, more than 50% of patients with PNH on C5 inhibitors have mild to moderate symptoms from PNH, and up to 20% still need occasional transfusions.